Ion Nitriding of CoCrMo Alloys

Kaya, Beril; Yılmaz, Süleyman; Ergun, Celaletdin

doi:10.4028/www.scientific.net/ddf.297-301.82

Cited by 2 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rutherford Backscattering Spectroscopy (RBS) and/ or Nuclear Reaction Analysis (NRA) using 1.35 MeV deuteron beams (5.5 MeV Tandem Accelerator) were also applied. For the determination of the nitrogen and oxygen content of the samples by NRA, the 14 N(d,p) 15 N, 14 N(d,a) 12 C, and 16 O(d,p) 17 O nuclear reactions were used. [35] Structural and topographical changes on the surfaces of plasma nitrided, oxidized, and double-treated CoCrMo samples were studied by Scanning Electron Microscopy (SEM) (Philips XL-305 FEG).…”

Section: B Sample Characterizationmentioning

confidence: 99%

“…Nitrogen implantation is one of many surface treatment techniques forming protective layers on Fe-and Co-based alloys and inducing enhanced surface properties, especially improved mechanical properties, without affecting the bulk. [5,9,10] Plasma-assisted nitriding [6,[11][12][13][14][15][16][17][18][19] and plasma-based ion implantation (PBII) [15,[19][20][21] are found to improve considerably the mechanical properties of CoCr alloys (e.g., wear and fatigue resistance) producing thick modified surface layers. Furthermore, both surface treatment techniques can be achieved on complex shape parts and significantly improve the tribological and corrosion properties of the treated surfaces.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Influence of Plasma-Based Nitriding and Oxidizing Treatments on the Mechanical and Corrosion Properties of CoCrMo Biomedical Alloy

Noli

Pichon

Öztürk

2018

Metall Mater Trans A

View full text Add to dashboard Cite

Plasma-based nitriding and/or oxidizing treatments were applied to CoCrMo alloy to improve its surface mechanical properties and corrosion resistance for biomedical applications. Three treatments were performed. A set of CoCrMo samples has been subjected to nitriding at moderate temperatures (~400°C). A second set of CoCrMo samples was oxidized at 395°C in pure O 2 . The last set of CoCrMo samples was nitrided and subsequently oxidized under the experimental conditions of previous sets (double treatment). The microstructure and morphology of the layers formed on the CoCrMo alloy were investigated by X-ray diffraction, Atomic Force Microscopy, and Scanning Electron Microscopy. In addition, nitrogen and oxygen profiles were determined by Glow Discharge Optical Emission Spectroscopy, Rutherford Backscattering Spectroscopy, Energy-Dispersive X-ray, and Nuclear Reaction Analysis. Significant improvement of the Vickers hardness of the CoCrMo samples after plasma nitriding was observed due to the supersaturated nitrogen solution and the formation of an expanded FCC c N phase and CrN precipitates. In the case of the oxidized samples, Vickers hardness improvement was minimal. The corrosion behavior of the samples was investigated in simulated body fluid (0.9 pct NaCl solution at 37°C) using electrochemical techniques (potentiodynamic polarization and cyclic voltammetry). The concentration of metal ions released from the CoCrMo surfaces was determined by Instrumental Neutron Activation Analysis. The experimental results clearly indicate that the CoCrMo surface subjected to the double surface treatment consisting in plasma nitriding and plasma oxidizing exhibited lower deterioration and better resistance to corrosion compared to the nitrided, oxidized, and untreated samples. This enhancement is believed to be due to the formation of a thicker and more stable layer.

show abstract

Section: B Sample Characterizationmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The Influence of Plasma-Based Nitriding and Oxidizing Treatments on the Mechanical and Corrosion Properties of CoCrMo Biomedical Alloy

Noli

Pichon

Öztürk

2018

Metall Mater Trans A

View full text Add to dashboard Cite

show abstract

“…Hepatocellular carcinoma (HCC) accounts for 75–90% of all primary liver cancer cases and is the third leading cause of cancer-related mortality worldwide [1–3]. In approximately 70–90% of cases, HCC occurs in patients with chronic liver disease and cirrhosis; hence, the major risk factors for HCC are chronic infection with hepatitis B and C viruses (HBV, HCV), excessive alcohol intake, obesity, type 2 diabetes, and smoking [1].…”

Section: Introductionmentioning

confidence: 99%

Atezolizumab in Combination with Bevacizumab for the Management of Patients with Hepatocellular Carcinoma in the First-Line Setting: Systematic Literature Review and Meta-Analysis

Vogel¹,

Finn²,

Zumofen³

et al. 2023

Liver Cancer

View full text Add to dashboard Cite

Background & aims: The objective of this systematic literature review (SLR) and network meta-analysis (NMA) is to compare randomised controlled trial evidence for atezolizumab-bevacizumab with globally relevant pharmacological comparators for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). Methods: Randomised controlled trials investigating first-line treatment of HCC in adults with no prior systemic treatment were eligible for inclusion into the SLR and were retrieved from Embase, MEDLINE, and Evidence Based Medicine (EBM) Reviews. Interventions of interest for the NMA included atezolizumab-bevacizumab, sorafenib, lenvatinib, durvalumab (including in combination with tremelimumab), cabozantinib (including in combination with atezolizumab), camrelizumab (including in combination with rivoceranib), pembrolizumab (including in combination with lenvatinib) and tislelizumab. Random effects NMA was conducted for survival endpoints within a Bayesian framework with an informative prior distribution for between study heterogeneity. The hazard ratios for relative treatment effect were estimated with 95% credible intervals (CrIs). Results: The SLR identified 49 studies, of which eight formed a connected evidence network permitting the indirect treatment comparison of atezolizumab-bevacizumab with comparators of interest. The indirect comparisons suggested an improved overall survival (OS) with atezolizumab-bevacizumab versus most comparators. All indirect treatment comparison results for atezolizumab-bevacizumab included the null value within the 95% CrI (n=1) for OS and progression free survival (PFS). Conclusions: The results of the NMA indicate atezolizumab-bevacizumab is associated with superior or comparable OS and PFS together with a manageable safety profile compared with globally relevant comparators in the unresected HCC indication. The findings support that atezolizumab-bevacizumab remains standard of care for the management of first-line unresectable HCC patients.

show abstract

Ion Nitriding of CoCrMo Alloys

Cited by 2 publications

References 15 publications

The Influence of Plasma-Based Nitriding and Oxidizing Treatments on the Mechanical and Corrosion Properties of CoCrMo Biomedical Alloy

The Influence of Plasma-Based Nitriding and Oxidizing Treatments on the Mechanical and Corrosion Properties of CoCrMo Biomedical Alloy

Atezolizumab in Combination with Bevacizumab for the Management of Patients with Hepatocellular Carcinoma in the First-Line Setting: Systematic Literature Review and Meta-Analysis

Contact Info

Product

Resources

About